MAPT and Alzheimer disease: Regarding prognosis in the conflicting biomarker categories, in our study the percentage of MCI patients classified as IAP or SNAP who converted to AD was not very different from each other (close to 50%) and did not differ much whether CSF Aβ42 alone or the Aβ42/40 ratio, combined with Tau and p-Tau, was used.